The effects of interleukin-2 therapy on the viral reservoir in HIV+ patients

Biomedicine and Pharmacotherapy

Volumn 54, Issue 6, 2000, Pages 316-320

  Zanussi, S ^a   De Paoli, P ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

HIV; Interleukin 2; Molecular biology; Viral reservoir

Indexed keywords

ANTIRETROVIRUS AGENT; INTERLEUKIN 2; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; BLOOD; CELL ACTIVATION; DRUG EFFECT; ERADICATION THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOTHERAPY; LYMPHOID TISSUE; MOLECULAR BIOLOGY; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; VIREMIA; VIRUS CULTURE; VIRUS DNA CELL DNA INTERACTION;

EID: 0033855855     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0753-3322(00)80054-2     Document Type: Article

References (41)

1. Rapid turnover of plasma virions and CD4 lymphocytes in HIV infection
2. HIV viral load in clinical practice
3. Reduction of HIV in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure
4. HIV-1 and HAART: A time to cure, a time to kill
5. HIV-1 replication in patients with undetectable plasma virus receiving HAART
6. Persistence of HIV-1 transcription in PBMCs in patients receiving potent antiretroviral therapy
7. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy
8. HIV-1 entry into quiescient primary lymphocytes: Molecular analysis reveals a labile, latent viral structure
9. Quiescent T lymphocytes as an inducible virus reservoir in HIV-1 infection
10. Molecular mechanisms for the regulation of HIV replication, persistence and latency
11. Constant mean viral copy number per infected cell in tissues regardless of high, low, or undetectable plasma HIV RNA
12. Presence of an inducible HIV-1 latent reservoir during HAART
13. Detection of infectious HIV in circulating monocytes from patients on prolonged highly active antiretroviral therapy
14. Induction of HIV-replication in latently infected CD4+ T cells using a combination of cytokines
15. Increased CD4 lymphocytes with intermittent courses of IL-2 in patients with HIV infection - A preliminary study
16. A randomized trial of high versus low dose subcutaneous IL-2 outpatient therapy for early HIV-1 infection
17. Dynamics of provirus load and lymphocyte subsets after IL-2 treatment in HIV-infected patients
18. Effect of IL-2 on the pool of latently infected, resting CD4+ T cells in HIV-1 infected patients receiving HAART
19. Can IL-2 smoke out HIV reservoirs?
20. Use of IL-2 in patients with AIDS
21. Therapy of AIDS with recombinant IL-2
22. Cytokine modulation of HIV expression
23. HIV replication in IL-2 stimulated PBMCs is driven in an autocrine/paracrine manner by endogenous cytokines
24. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection
25. Identification of a reservoir for HIV-1 in patients on HAART
26. Quantitative assessment of integrated and episomal HIV-DNA
27. Peripheral blood mononuclear cell HIV-1 proviral DNA quantification by PCR: Relationship to immunodeficiency and drug effect
28. Quantification of HIV-1 viral load in lymphoid and blood cells: Assessment during four-drug combination therapy
29. Levels of HIV-infected PBMCs remain stable during the natural history of HIV infection
30. Provirus copy number to predict disease progression in asymptomatic HIV-1 infection
31. HIV-1 proviral copy number in blood mononuclear cells from AIDS patients on zidovudine therapy
32. Provirus load changes in untreated and zidovudine treated HIV-1 infected patients
33. Cellular proviral HIV-1 DNA load persists after long-term RT-inhibitor therapy in HIV-1 infected persons
34. Decay characteristics of HIV-1 infected compartments during combination therapy
35. Decay of HIV-1 DNA in patients receiving suppressive antiretroviral therapy
36. Quantification of integrated and total HIV-1 DNA after long-term HAART in HIV-1 infected patients
37. The effects of two-year antiretroviral combination therapies on HIV- DNA levels
38. Loss of inducible virus in CD45RA naive cells after HIV-1 entry accounts for preferential replication in CD45R0 memory cells
39. Preferential replication of HIV-1 in the CD45R0 memory cell subset of primary CD4 lymphocytes in vitro
40. Kinetics of productive and latent HIV infection in lymphatic tissue and peripheral blood during triple-drug combination therapy with or without IL-2
41. Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1 infected patients on potent antiretroviral therapy